Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Liquidia’s clinical milestones can feel like navigating a labyrinth of FDA language, trial statistics, and licensing footnotes. Each new Liquidia 8-K material events explained notice might include pivotal updates on YUTREPIA’s path to approval, while a single Form 4 could show an insider buying shares ahead of a data read-out. Our AI-driven platform decodes those complexities so you can focus on what matters, delivering Liquidia SEC filings explained simply the moment they hit EDGAR.
Stop skimming hundred-page PDFs. Stock Titan’s engine extracts the cash-runway tables from every Liquidia quarterly earnings report 10-Q filing, highlights trial spend buried inside the Liquidia annual report 10-K simplified, and flags Liquidia proxy statement executive compensation details side by side with peer data. Need to watch executive moves? Receive Liquidia Form 4 insider transactions real-time alerts that list each Liquidia executive stock transactions Form 4 in context—share price, option type, and historical buying patterns.
Whether you’re comparing treprostinil royalty streams or assessing dilution risk from future capital raises, our coverage spans every filing type—from 10-K, 10-Q, and 8-K to Section 16 reports—updated in seconds. AI-powered summaries, keyword search across historical documents, and exportable tables let you perform rapid Liquidia earnings report filing analysis without specialized training. Use cases include:
- Monitoring Liquidia insider trading Form 4 transactions before trial announcements
- Understanding Liquidia SEC documents with AI for quicker valuation models
- Tracking manufacturing scalability disclosures tied to PRINT® technology
Liquidia Corporation reported initial commercial sales following FDA approval of YUTREPIA and posted early-stage revenue while remaining loss-making. YUTREPIA was approved by the FDA on May 23, 2025 and commercially launched on June 2, 2025; product sales for the three months ended June 30, 2025 were $6.5 million and service revenue (from the Sandoz promotion agreement) was $2.3 million, producing total revenue of $8.8 million for the quarter and $12.0 million for the six months.
The company reported a net loss of $41.6 million for the quarter and $79.9 million for the six months, driving an accumulated deficit of $637.3 million. Cash and cash equivalents were $173.4 million and total assets were $257.4 million. Total liabilities rose to $242.2 million driven by long-term debt (carrying value $193.6 million) and litigation finance obligations. Stockholders' equity declined to $15.2 million. The company disclosed ongoing patent and related litigation with United Therapeutics that could affect YUTREPIA, an indemnification asset of $8.3 million and a litigation finance payable of $8.0 million. Management states available cash and anticipated YUTREPIA inflows are expected to satisfy obligations for at least the next twelve months, and the HCR revenue interest financing contains a $15.0 million minimum cash covenant.
Liquidia Corporation furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update. The press release is attached to the Form 8-K as Exhibit 99.1, and the filing includes an Inline XBRL cover page file as Exhibit 104.
The disclosure in Item 2.02 is furnished rather than filed and therefore is not deemed filed under Section 18 of the Exchange Act. No financial figures, operational details or transaction terms are included in this 8-K itself; the substantive results and update are contained in the referenced press release.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
